Arrowhead Presents Positive Plozasiran Data

Arrowhead Pharmaceuticals presented new positive clinical data for Plozasiran at the 94th European Atherosclerosis Society Congress. The data support the use of Plozasiran in patients with moderate-to-severe renal impairment or moderate hepatic impairment without dose adjustment, and a case report suggests preconception exposure may lead to sustained lowering of fasting triglyceride levels throughout pregnancy. These findings expand the potential patient population for Plozasiran, which is already approved in several countries and has received Breakthrough Therapy designation from the United States — Food and Drug Administration for severe hypertriglyceridemia. The European Union — European Medicines Agency has also adopted a positive opinion for its European Marketing Authorization.